Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation
/in Dendritic Cells, International Publications /von 2007-12-21 / J. Leukoc. Biol. 2008 Mar;83(3):742-54Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas
/in Glioblastoma, International Publications /von 2007-12-19 / J Transl Med 2007 Dec;5:67Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial
/in Cervical Cancer, Dendritic Cells, International Publications /von 2007-12-05 / J Virol 2008 Feb;82(4):1968-79Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma
/in Colorectal Cancer, International Publications /von 2007-12-03 / Immunol. Lett. 2008 Feb;116(1):24-32Experimental evidence for the efficacy of combined therapy of CPT-11 and hyperthermia for squamous cell carcinoma of the esophagus
/in Esophageal Carcinoma, Hyperthermia, International Publications /von 2007-12-01 / Hepatogastroenterology 2007 Dec;54(80):2272-5Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D breast cancer cell line model indicate their potential as anti-tumour vaccines
/in Breast Cancer, International Publications /von 2007-12-01 / Int. J. Oncol. 2007 Dec;31(6):1357-65RF-power and temperature data analysis of 444 patients with primary cervical cancer: deep hyperthermia using the Sigma-60 applicator is reproducible
/in Cervical Cancer, International Publications /von 2007-12-01 / Int J Hyperthermia 2007 Dec;23(8):623-43[Study on the cell apoptosis induced by intracellular hyperthermia in human lung adenocarcinoma SPC-A1 cells]
/in International Publications, NSCLC /von 2007-12-01 / Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2007 Dec;24(6):1305-8
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution